Table 5.
Clinical changes from Visit 1 to Visit 8 (all subjects, n = 234)
| Characteristics | Visit 1 | Visit 8 | p a value |
|---|---|---|---|
| Daily dose of inhaled budesonide equivalent (μ ± SD) | 813.3(±247.5) | 1,295.5(±754.8) | <0.01 |
| Any oral corticosteroid requirement in the year before n(%) | 86 (37) | 146 (62) | <0.01 |
| Number of emergency room visits due to asthma in the year before M(p 25 -p 75 ) | 0 (0–2) | 0 (0–1) | <0.01 |
| Proportion of patients that need emergency room visits due to asthma in the year before n(%) | 113 (48) | 73 (31) | <0.01 |
| Proportion of patients that need ICU admission due to asthma in the year before n(%) | 2 (1) | 4 (2) | 0.69 |
| AQLQ scores M(p 25 -p 75 ) | 4 (3–5) | 5 (3–6) | <0.01 |
| ACQ scores M(p 25 -p 75 ) | 2 (1–3) | 1 (0–2) | <0.01 |
| Proportion of patients with ACQ score ≥ 1.5 n(%) | 141 (60) | 87 (37) | <0.01 |
| Proportion of patients with ACQ score ≤ 0.75 n(%) | 44 (19) | 97 (42) | <0.01 |
Note: ACQ asthma control questionnaire, AQLQ asthma quality of life questionnaire. aMcNemar and Wilcoxon Test